Clinical Development

Strategic CRO takes $100m hit from Pfizer's shelved PCSK9 candidate

Image: iStock/raphspam

Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.

HPCTC adopts biometric fingerprint tech to register patients

HPCTC adopts biometric fingerprint tech to register patients

iStock/wildpixel

Quotient buys QS Pharma in latest US expansion move

Graham Cotton, Senior R&D Group Leader, Almac Discovery; Tracy Robson; and Professor Tim Harrison, VP Discovery Chemistry, Almac Discovery.

Almac Discovery and RCSI enter research collaboration

PRA and Takeda establish new joint venture in Japan

PRA and Takeda establish new joint venture in Japan

ACRP developed CRA framework open for comment

ACRP develops framework in response to 'significant' CRA shortage

Orgenesis granted €12.3m for GMP production ahead of clinical trials

Orgenesis granted €12.3m for GMP production ahead of clinical trials

CRO Beaufort certified under ISO 9001:2015

CRO Beaufort certified under ISO 9001:2015

Parkinson’s research slowed by study design flaws

Report: study design flaws slowing Parkinson's research

Parexel launches RTSM mobile app

Parexel launches RTSM mobile app

More Clinical Development